Working… Menu

Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00377598
Recruitment Status : Completed
First Posted : September 18, 2006
Last Update Posted : February 2, 2012
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the efficacy of TAK-583, once daily (QD), in relieving pain in subjects with postherpetic neuralgia.

Condition or disease Intervention/treatment Phase
Neuralgia, Postherpetic Drug: TAK-583 Drug: Placebo Phase 2 Phase 3

Detailed Description:

Postherpetic neuralgia is defined as neuropathic pain still present 3 months following healing of the herpes zoster rash. Symptoms of postherpetic neuralgia may include a complex combination of symptoms, including a deep aching, shooting or burning pain, sensory deficits, hyperalgesia, allodynia, paresthesia, and dysesthesia. Postherpetic neuralgia is more common in the elderly, and it can have a debilitating effect on a patient. The most commonly prescribed treatments are tricyclic antidepressants and anticonvulsants, however these treatments are effective in approximately half of subjects and may also have undesirable side effects (eg, dizziness and somnolence).

TAK-583 is a synthetic compound under development by Takeda Global Research & Development Center, Inc. as a treatment for neuropathic pain and for delaying the progression of diabetic neuropathy.

Individuals who want to participate in this study will be required to provide written informed consent. Study participation is anticipated to be about 11 Weeks. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, vital signs, body height and weight, physical examinations and electrocardiograms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 399 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Double Blind, Placebo Controlled, Dose-Ranging Study in Subjects With Postherpetic Neuralgia (PHN) to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Four Doses of TAK-583, Compared With Placebo
Study Start Date : October 2006
Actual Primary Completion Date : February 2008
Actual Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shingles

Arm Intervention/treatment
Experimental: TAK-583 5 mg QD Drug: TAK-583
TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks

Experimental: TAK-583 25 mg QD Drug: TAK-583
TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks

Experimental: TAK-583 50 mg QD Drug: TAK-583
TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks

Experimental: TAK-583 100 mg QD Drug: TAK-583
TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks

Placebo Comparator: Placebo QD Drug: Placebo
TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks

Primary Outcome Measures :
  1. Change from Baseline in average daily pain intensity score for the previous 7 days [ Time Frame: Week 8 or Final Visit ]

Secondary Outcome Measures :
  1. Change from baseline to each study visit in average daily pain intensity score for the last 7 days [ Time Frame: At All Visits ]
  2. Change from baseline in pain assessment as assessed by Short form McGill Pain Questionnaire [ Time Frame: Week 8 or Final Visit ]
  3. Change from baseline in weekly mean sleep interference scores (assessed on an 11-point numerical scale in the subject's sleep diary) [ Time Frame: Week 8 or Final Visit ]
  4. Clinician and subject global impression of change using a 7-point scale [ Time Frame: Week 8 or Final Visit ]
  5. Change from baseline in quality of life as assessed by Short Form-36 [ Time Frame: Week 8 or Final Visit ]
  6. Change from baseline in Profile of Mood States [ Time Frame: Week 8 or Final Visit ]
  7. Proportions of subjects with at least 30% and 50% reduction from baseline in average daily pain intensity score [ Time Frame: Week 8 or Final Visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female subjects with postherpetic neuralgia whose pain has been present for >3 months following healing of the herpes zoster rash.
  • Subjects with an mean pain intensity score of 4 or more (determined from at least 4 daily recordings of pain intensity on an 11-point numerical scale over the preceding 7 days) during the baseline phase.
  • Subjects aged 50 years and above.
  • The female subject is not of child-bearing potential (eg, sterilized, postmenopausal).

Exclusion Criteria:

  • Malignancy within the past 2 years with the exception of basal cell carcinoma.
  • Subjects who have undergone neurolytic or neurosurgical therapy for postherpetic neuralgia.
  • Clinically significant, actively treated or unstable hepatic, biliary, respiratory, renal, rheumatologic, or hematologic illnesses, or unstable cardiovascular disease as assessed by the investigator.
  • WBC less than 2500, ANC less than 1500, platelets less than 100,000; ALT, AST or alkaline phosphatase greater than 1.5x ULN; total bilirubin greater than or equal to 1.2 times the upper limit of normal (excluding Gilbert's Disease); predicted GFR using Cockcroft and Gault formula less than or equal to 40 mL/min.
  • Subjects with greater than 5 red blood cells per high-power field on urinalysis.
  • Subjects with an albumin/creatinine ratio in an untimed ("spot") morning urine specimen greater than the upper limit of normal.
  • Subjects who are immunocompromised or have clinically significant haematological abnormalities.
  • Subjects with a history of HIV infection.
  • Subjects with a positive hepatitis panel (including hepatitis B surface antigen, antibody to hepatitis B core antigen, antibody to hepatitis B surface antigen, or antibody to hepatitis C virus), except subjects with positive antibodies to hepatitis B surface antigen who have received hepatitis B vaccination and who have no history of serological evidence of liver disease.
  • Subjects having other severe pain which may impair the self assessment of the pain due to postherpetic neuralgia.
  • Subjects who have participated in a clinical trial for an investigational drug and/or agent within 30 days prior to baseline.
  • Subjects who have received TAK-583 in a previous clinical study.
  • Subjects who have donated more than 400 mL of blood in the 90 days prior to the beginning of the study.
  • Subjects who have a history of alcohol or illicit drug abuse in the past 2 years
  • Clinically significant abnormal 12 lead electrocardiogram, including QT interval corrected for heart rate greater than 450 ms that is confirmed on a repeat electrocardiogram.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00377598

Layout table for location information
Australia, New South Wales
Sydney, New South Wales, Australia
Australia, Queensland
Kipparing, Queensland, Australia
Maroochydore, Queensland, Australia
Australia, Victoria
Box Hill, Victoria, Australia
Carlton, Victoria, Australia
Fitzroy, Victoria, Australia
Australia, Western Australia
Perth, Western Australia, Australia
Sofia, Bulgaria
Czech Republic
Hradec Kralove, Czech Republic
Moravska Ostrava, Czech Republic
Olomouc, Czech Republic
Ostrava, Czech Republic
Plzen, Czech Republic
Berlin, Germany
Dresden, Germany
Frankfurt, Germany
Goerlitz, Germany
Hamburg, Germany
Jena, Germany
Leipzig, Germany
Magdeburg, Germany
Schwerin, Germany
Arnhem, Netherlands
Breda, Netherlands
Roosendaal, Netherlands
Rotterdam, Netherlands
Stadskanaal, Netherlands
Utrecht, Netherlands
Gdansk, Poland
Lublin, Poland
Mosina k/Poznania, Poland
Poznan, Poland
Russian Federation
Kazan, Russian Federation
Moscow, Russian Federation
St. Petersburg, Russian Federation
South Africa
Bloemfontein, Free State, South Africa
Pretoria, Gauteng, South Africa
Amanzimtori, Kwa-Zulu Natal, South Africa
Durban, Kwa-Zulu Natal, South Africa
Breyten, Mpumalanga, South Africa
Nelspruit, Mpumalanga, South Africa
Polokwane, Western Cape, South Africa
Worcester, Western Cape, South Africa
United Kingdom
Chichester, United Kingdom
Darlington, United Kingdom
Glasgow, United Kingdom
Plymouth, United Kingdom
Solihull, United Kingdom
Sponsors and Collaborators
Layout table for investigator information
Study Director: VP Clinical Science Takeda Global Research & Development Center
Layout table for additonal information
Responsible Party: Takeda Identifier: NCT00377598    
Other Study ID Numbers: TAK-583-EC201
2005-005863-26 ( EudraCT Number )
U1111-1127-6187 ( Registry Identifier: WHO )
First Posted: September 18, 2006    Key Record Dates
Last Update Posted: February 2, 2012
Last Verified: January 2012
Keywords provided by Takeda:
Herpes Zoster
Drug Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuralgia, Postherpetic
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Neurologic Manifestations